Skip to content

Study · Randomized controlled trial · n = 174 · 2013

11 results

Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.

Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Ciccarelli L, D'Angelo A, Fogari E, Maffioli P

Canadian journal of physiology and pharmacology23 Apr 2013Cited by 20 (Europe PMC)

PMID23984793 (opens in a new tab)DOI10.1139/cjpp-2012-0300 (opens in a new tab)PepBankPUB-23984793
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide reduced body mass more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide reduced body mass more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody mass
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months, a combination of exenatide and metformin produced a better decrease in body mass, BMI, glycemic control, FPI, FPPr, FPPr/FPI ratio, HOMA-IR, and glucagon level.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide reduced BMI more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide reduced BMI more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBMI
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months, a combination of exenatide and metformin produced a better decrease in body mass, BMI, glycemic control, FPI, FPPr, FPPr/FPI ratio, HOMA-IR, and glucagon level.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide improved glycemic control more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide improved blood sugar control more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedGlycemic control
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months, a combination of exenatide and metformin produced a better decrease in body mass, BMI, glycemic control, FPI, FPPr, FPPr/FPI ratio, HOMA-IR, and glucagon level.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide reduced fasting plasma insulin more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide reduced fasting insulin more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting plasma insulin
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months, a combination of exenatide and metformin produced a better decrease in body mass, BMI, glycemic control, FPI, FPPr, FPPr/FPI ratio, HOMA-IR, and glucagon level.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide reduced fasting plasma proinsulin more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide reduced fasting proinsulin more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting plasma proinsulin
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months, a combination of exenatide and metformin produced a better decrease in body mass, BMI, glycemic control, FPI, FPPr, FPPr/FPI ratio, HOMA-IR, and glucagon level.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide reduced the fasting proinsulin-to-insulin ratio more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide reduced the proinsulin-to-insulin ratio more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseProinsulin to insulin ratio
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months, a combination of exenatide and metformin produced a better decrease in body mass, BMI, glycemic control, FPI, FPPr, FPPr/FPI ratio, HOMA-IR, and glucagon level.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide reduced HOMA-IR more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide reduced the HOMA-IR insulin resistance measure more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHOMA-IR
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months, a combination of exenatide and metformin produced a better decrease in body mass, BMI, glycemic control, FPI, FPPr, FPPr/FPI ratio, HOMA-IR, and glucagon level.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide reduced glucagon more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide reduced glucagon more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlucagon
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months, a combination of exenatide and metformin produced a better decrease in body mass, BMI, glycemic control, FPI, FPPr, FPPr/FPI ratio, HOMA-IR, and glucagon level.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide increased HOMA-β more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide increased HOMA-β more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHOMA-β
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment with exenatide + metformin was superior to the placebo + metformin in increasing HOMA-β, C-peptide, and β-cell function.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide increased C-peptide more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide increased C-peptide more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseC-peptide
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment with exenatide + metformin was superior to the placebo + metformin in increasing HOMA-β, C-peptide, and β-cell function.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes on metformin, exenatide increased β-cell function more than placebo.

    In plain wordsIn patients with diabetes on metformin, exenatide improved insulin-producing cell function more than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Increaseβ-cell function
    Study

    n = 174

    Comparator
    Placebo plus metformin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 μg twice daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment with exenatide + metformin was superior to the placebo + metformin in increasing HOMA-β, C-peptide, and β-cell function.
    1 context sentence
    Summary · context
    After a run-in period with metformin, 174 patients with type-2 diabetes were randomly distributed to either a group receiving exenatide at 10 μg twice daily, or a group receiving the placebo, for 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.